Harbourbiomed set up a subsidiary Nona biological

On November 14, Harbourbiomed (ticker symbol: HK) announced the establishment of a wholly-owned subsidiary, Nona Biology, which will utilize its unique advantages and rich experience in the research and development of antibody-related fields by utilizing the Harbour Mice® transgenic mouse platform with human antibody and the new generation of self-developed immune cell connector dual anti-antibody platform HBICE®. Provides partners with complete preclinical drug development services from discovery to clinical research approval (I to ITM, Idea to IND).

Nona Biology creatively opens the industry-leading Harbour Mice® platform, and eliminates platform barriers with a more flexible business model as a partner, enabling the platform and technology to truly enable the discovery and development of the world's next generation of innovative therapies. It also provides an important option for maximising the value of the Harbour Mice® platform.

"The biopharmaceutical industry is moving toward more complex fully human biotherapeutics, such as bisspecific antibodies, antibody-coupled drug ADCs, and cell therapies including CAR-T, CAR-NK and mRNA," said Dr. Jinsong Wang, founder, Chairman and Chief Executive Officer of Hexatin Pharma. We have accumulated a lot of experience in global innovative biological drug research and development, and further establish and improve the technology platform system, whose value has been widely verified and applied by multinational pharmaceutical companies, biopharmaceutical companies and scientific research and academic institutions. Nona Bio is committed to providing open platform access to its peers, leveraging scarce platform technologies, innovative service models and strong team support to help partners drive global biotherapeutic innovation for the benefit of the entire industry and ultimately patients around the world."

Over the years, as a pioneer in the field of biotechnology innovation, HexinPharma has established and improved the technology platform system, and on this basis has created a globally competitive differentiated product pipeline. Its innovative research and development platform has been validated and applied by more than 50 multinational pharmaceutical companies, biopharmaceutical companies, scientific research and academic institutions, including Modena, Pfizer, Eli Lilly, Dana-Farber Cancer Research Center, etc. The platform has generated more than 10 clinical drug candidates.

Nona biological patent technology platform

Nona Bio provides one-stop solutions for antibody discovery, antibody engineering and antibody development. Its innovative R&D services cover a range of technology portfolio. Its core service is based on Harbour Mice®, the world's leading platform for transgenic mice with human antibodies, which produces classic human antibodies (H2L2) and human heavy chain antibodies (HCAb). It has broad application prospects in tumor immunotherapy, cell therapy, multi-specific antibody development, ADC drug research and development, etc. In addition, the immune cell connector platform (HBICE®) independently developed based on the HCAb platform also has unique advantages in the development of a new generation of bispecial antibodies.

By integrating these innovative technology platforms with a team of scientists with extensive experience in pharmaceutical research and development, Nona Bio provides quality services covering antigen preparation, animal immunity, single B cell screening, antibody development and engineering, medicinal properties and pharmacological evaluation.